Literature DB >> 29478242

Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.

H Horikawa1, Y Kurihara1, T Funakoshi1, N Umegaki-Arao1, H Takahashi1, A Kubo1, A Tanikawa1, N Kodani2,3, Y Minami2, S Meguro2, H Itoh2, K Izumi4, W Nishie4, H Shimizu4, M Amagai1, J Yamagami1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29478242     DOI： 10.1111/bjd.16479

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  12 in total

1.  Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.

Authors:  Ágnes Kinyó; Anita Hanyecz; Zsuzsanna Lengyel; Dalma Várszegi; Péter Oláh; Csaba Gyömörei; Endre Kálmán; Tímea Berki; Rolland Gyulai
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

Review 2.  Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Kaisa Tasanen; Outi Varpuluoma; Wataru Nishie
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 8.786

3.  Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.

Authors:  Yosuke Mai; Wataru Nishie; Kentaro Izumi; Hiroshi Shimizu
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

4.  Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.

Authors:  Christian D Sadik; Ewan A Langan; Victoria Grätz; Detlef Zillikens; Patrick Terheyden
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

5.  DPP-4 Inhibitor-associated Bullous Pemphigoid in a Hemodialysis Patient.

Authors:  Jun Usami; Yumiko Takezawa
Journal:  Intern Med       Date:  2019-10-15       Impact factor: 1.271

Review 6.  Milestones in Personalized Medicine in Pemphigus and Pemphigoid.

Authors:  Katja Bieber; Khalaf Kridin; Shirin Emtenani; Katharina Boch; Enno Schmidt; Ralf J Ludwig
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

Review 7.  Recent advances in the understanding and treatment of pemphigus and pemphigoid.

Authors:  Jun Yamagami
Journal:  F1000Res       Date:  2018-08-30

Review 8.  The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease.

Authors:  Kyle T Amber; Manuel Valdebran; Khalaf Kridin; Sergei A Grando
Journal:  Front Med (Lausanne)       Date:  2018-07-10

9.  More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.

Authors:  Ralf J Ludwig; Khalaf Kridin; Sascha Ständer; Enno Schmidt; Detlef Zillikens
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

10.  Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Authors:  Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Journal:  Dermatopathology (Basel)       Date:  2022-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.